Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing FDA-approved reference products. These products are designed to be used as alternatives to existing biologics, offering increased access to important medications at a potentially lower cost. Biosimilars undergo a rigorous development and approval process to ensure their safety, efficacy, and quality. These products have the potential to provide patients with more treatment options and improve overall healthcare affordability.